Expertise in
8
conditions

Dr. Joseph Muenzer

Pediatrics
101 Manning Dr, 
Chapel Hill, NC 
Accepting New Patients
Expertise in
8
conditions
101 Manning Dr, 
Chapel Hill, NC 

Overview

Joseph Muenzer is a Pediatrics provider practicing medicine in Chapel Hill, North Carolina.

Dr. Muenzer is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Mucopolysaccharidosis Type 2 (MPS II, Hunter Syndrome), Mucopolysaccharidoses (MPS), Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome), and Mucopolysaccharidosis Type 3A (MPS IIIA, Sanfilippo Syndrome A).

He is actively involved in clinical research, co-authoring 73 peer reviewed articles and participating in 7 clinical trials. Dr. Muenzer is currently accepting new patients.

Specialties

Pediatrics

Licenses

Pediatrics in NC

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Trillium
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

101 Manning Dr, Chapel Hill, NC 27599

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 1/2, Multicenter, Open-Label Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL310 in Pediatric Participants With Hunter Syndrome
A Phase 1/2, Multicenter, Open-Label Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL310 in Pediatric Participants With Hunter Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2025
Intervention Type: Drug
Study Drug: DNL310
Study Phase: Phase 1/Phase 2
A Prospective, Longitudinal Study of Potential Treatment-Responsive Biomarkers and Clinical Outcomes in Hunter Syndrome
A Prospective, Longitudinal Study of Potential Treatment-Responsive Biomarkers and Clinical Outcomes in Hunter Syndrome
Enrollment Status: Completed
Publish Date: June 10, 2024
Intervention Type: Other
A Phase I / 2, Multicenter, Open-label, Single-dose, Dose-ranging Study to Assess the Safety and Tolerability of SB-913, a rAAV2/6-based Gene Transfer in Subjects With Mucopolysaccharidosis II (MPS II)
A Phase I / 2, Multicenter, Open-label, Single-dose, Dose-ranging Study to Assess the Safety and Tolerability of SB-913, a rAAV2/6-based Gene Transfer in Subjects With Mucopolysaccharidosis II (MPS II)
Enrollment Status: Terminated
Publish Date: October 25, 2022
Intervention Type: Biological
Study Drug: SB-913
Study Phase: Phase 1/Phase 2
A Phase I/II, Randomized, Safety and Ascending Dose Ranging Study of Intrathecal Idursulfase-IT Administered in Conjunction With Intravenous Elaprase in Pediatric Patients With Hunter Syndrome and Cognitive Impairment
A Phase I/II, Randomized, Safety and Ascending Dose Ranging Study of Intrathecal Idursulfase-IT Administered in Conjunction With Intravenous Elaprase in Pediatric Patients With Hunter Syndrome and Cognitive Impairment
Enrollment Status: Completed
Publish Date: June 28, 2021
Intervention Type: Drug, Other
Study Phase: Phase 1/Phase 2
A Screening Study to Identify Pediatric Patients With Hunter Syndrome Who Demonstrate Evidence of Central Nervous System Involvement and Who Are Currently Receiving Treatment With Elaprase®
A Screening Study to Identify Pediatric Patients With Hunter Syndrome Who Demonstrate Evidence of Central Nervous System Involvement and Who Are Currently Receiving Treatment With Elaprase®
Enrollment Status: Completed
Publish Date: June 14, 2021
Intervention Type: Other, Behavioral
A Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Weekly and Every Other Week Dosing Regimens of Iduronate-2-Sulfatase Enzyme Replacement Therapy in Patients With MPS II
A Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Weekly and Every Other Week Dosing Regimens of Iduronate-2-Sulfatase Enzyme Replacement Therapy in Patients With MPS II
Enrollment Status: Completed
Publish Date: June 10, 2021
Intervention Type: Biological
Study Phase: Phase 2/Phase 3
An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy
An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy
Enrollment Status: Completed
Publish Date: June 10, 2021
Intervention Type: Biological
Study Phase: Phase 2/Phase 3
View 6 Less Clinical Trials

73 Total Publications

Differential COVID-19 Outcomes Across Lysosomal Disorders.
Differential COVID-19 Outcomes Across Lysosomal Disorders.
Journal: medRxiv : the preprint server for health sciences
Published: July 03, 2026
Similar Doctors
Expertise in
10
conditions
Expertise in
10
conditions
Referral may be required

Duke Health Integrated Practice Inc

40 Duke Medicine Cir, 
Durham, NC 
 (9.5 miles away)
919-684-8111
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Priya Kishnani is a Pediatrics provider practicing medicine in Durham, North Carolina. Dr. Kishnani is highly rated in 10 conditions, according to our data. Her clinical expertise encompasses Pompe Disease, Glycogen Storage Disease Type 3, Hypophosphatasia (HPP), Glycogen Storage Disease Type 9, and Splenectomy. Dr. Kishnani is currently accepting new patients.

Expertise in
10
conditions
Expertise in
10
conditions
Referral may be required

UNC Hospitals Pulmonary Function Lab

101 Manning Dr, 
Chapel Hill, NC 
 (0.1 miles away)
919-966-5063
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Matthew Laughon is a Pediatrics provider practicing medicine in Chapel Hill, North Carolina. Dr. Laughon is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Premature Infant, Bronchopulmonary Dysplasia, High Blood Pressure in Infants, and Intraventricular Hemorrhage of the Newborn. Dr. Laughon is currently accepting new patients.

Expertise in
9
conditions
Expertise in
9
conditions
Referral may be required

University Of North Carolina At Chapel Hill

143 W Franklin St, 
Chapel Hill, NC 
 (0.7 miles away)
919-966-4135
Languages Spoken:
English
See accepted insurances

Maria Escolar is a Pediatrics provider practicing medicine in Chapel Hill, North Carolina. Dr. Escolar is highly rated in 9 conditions, according to our data. Her clinical expertise encompasses Mucopolysaccharidosis Type 2 (MPS II, Hunter Syndrome), Mucopolysaccharidoses (MPS), Mucopolysaccharidosis Type 3 (MPS III, Sanfilippo Syndrome), and Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome).

Frequently Asked Questions about Dr. Joseph Muenzer

How do I make an appointment with Dr. Joseph Muenzer?

You can book an appointment with Dr. Joseph Muenzer by calling their office at 919-966-4131. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Joseph Muenzer a top-rated expert for Mucopolysaccharidosis Type 2 (MPS II, Hunter Syndrome)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Joseph Muenzer is classified as an Elite expert for Mucopolysaccharidosis Type 2 (MPS II, Hunter Syndrome), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Joseph Muenzer specialize in?

While Dr. Joseph Muenzer is a Pediatrics, they have specific expertise in Mucopolysaccharidosis Type 2 (MPS II, Hunter Syndrome), Mucopolysaccharidoses (MPS), and Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Pediatrics.

Does Dr. Joseph Muenzer participate in research or clinical trials?

Yes. Dr. Joseph Muenzer has published 73 articles and abstracts on conditions like Mucopolysaccharidosis Type 2 (MPS II, Hunter Syndrome). You can view a list of Dr. Joseph Muenzer's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Joseph Muenzer accept my insurance?

Dr. Joseph Muenzer accepts most major insurance plans, including Blue Cross Blue Shield and Humana. We recommend calling the office directly at 919-966-4131 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Muenzer's expertise for a condition
ConditionClose
View All 7 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile